Advanced search
Publication Cover
Future Neurology Volume 14, 2019 - Issue 2
Submit an article Journal homepage
1,598
Views
0
CrossRef citations to date
0
Altmetric
Editorial

Funding for Spinal Muscular Atrophy Research must Continue

Melissa Bowerman1 School of Medicine, Keele University, Keele, ST5 5BG, UK;2 Institute for Science & Technology in Medicine, Stoke-on-Trent, ST4 7QB, UK;3 Wolfson Centre for Inherited Neuromuscular Disease, RJAH Orthopaedic Hospital, Oswestry, SY10 7AG, UKCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-3579-6403View further author information
ORCID Icon
Article: FNL10 | Received 08 Feb 2019, Accepted 22 Feb 2019, Published online: 05 Jun 2019

References

  • PearnJ. Incidence, prevalence, and gene frequency studies of chronic childhood spinal muscular atrophy. J. Med. Genet. 15(6), 409–413 (1978).
  • CrawfordTO, PardoCA. The neurobiology of childhood spinal muscular atrophy. Neurobiol. Dis. 3(2), 97–110 (1996).
  • LefebvreS, BürglenL, ReboulletSet al.Identification and characterization of a spinal muscular atrophy-determining gene. Cell. 80(1), 155–165 (1995).
  • LorsonCL, HahnenE, AndrophyEJ, WirthB. A single nucleotide in the SMN gene regulates splicing and is responsible for spinal muscular atrophy. Proc. Natl Acad. Sci. USA 96(11), 6307–6311 (1999).
  • SchrankB, GötzR, GunnersenJMet al.Inactivation of the survival motor neuron gene, a candidate gene for human spinal muscular atrophy, leads to massive cell death in early mouse embryos. Proc. Natl Acad. Sci. USA 94(18), 9920–9925 (1997).
  • LefebvreS, BurletP, LiuQet al.Correlation between severity and SMN protein level in spinal muscular atrophy. Nat. Genet. 16(3), 265–269 (1997).
  • WoodMJA, TalbotK, BowermanM. Spinal muscular atrophy: antisense oligonucleotide therapy opens the door to an integrated therapeutic landscape. Hum. Mol. Genet. 26(R2), R151–R159 (2017).
  • GidaroT, ServaisL. Nusinersen treatment of spinal muscular atrophy: current knowledge and existing gaps. Dev. Med. Child Neurol. 61(1), 19–24 (2019).
  • FinkelRS, MercuriE, DarrasBTet al.Nusinersen versus sham control in infantile-onset spinal muscular atrophy. N. Engl. J. Med. 377(18), 1723–1732 (2017).
  • FinkelRS, ChiribogaCA, VajsarJet al.Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study. Lancet Lond. Engl. 388(10063), 3017–3026 (2016).
  • BowermanM, BeckerCG, Yáñez-MuñozRJet al.Therapeutic strategies for spinal muscular atrophy: SMN and beyond. Dis. Model. Mech. 10(8), 943–954 (2017).
  • PechmannA, LangerT, SchorlingDet al.Evaluation of children with SMA type 1 under treatment with Nusinersen within the expanded access program in germany. J. Neuromuscul. Dis. 5(2), 135–143 (2018).
  • MessinaS, PaneM, SansoneVet al.Expanded access program with Nusinersen in SMA type I in Italy: strengths and pitfalls of a successful experience. Neuromuscul. Disord. 27(12), 1084–1086 (2017).
  • Aragon-GawinskaK, SeferianAM, DaronAet al.Nusinersen in patients older than 7 months with spinal muscular atrophy type 1: a cohort study. Neurology 91(14), e1312–e1318 (2018).
  • FarrarMA, TeohHL, CareyKAet al.Nusinersen for SMA: expanded access programme. J. Neurol. Neurosurg. Psychiatry. 89(9), 937–942 (2018).
  • BertiniE, HwuW-L, ReynaSPet al.Efficacy and safety of nusinersen in infants with presymptomatic spinal muscular atrophy (SMA): Interim results from the NURTURE study. Eur. J. Paediatr. Neurol. 21, e14 (2017).
  • MontesJ, YoungSD, MazzoneEet al.Ambulatory function and fatigue in nusinersen-treated children with spinal muscular atrophy. (P2.322). Neurology 90(15 Supplement),  P2.322 (2018).
  • PacioneM, SiskindCE, DayJW, TaborHK. Perspectives on Spinraza (Nusinersen) treatment study: views of individuals and parents of children diagnosed with spinal muscular atrophy. J. Neuromuscul. Dis. 6(1), 119–131 (2018).
  • HamiltonG, GillingwaterTH. Spinal muscular atrophy: going beyond the motor neuron. Trends Mol. Med. 19(1), 40–50 (2013).
  • Christie-BrownV, MitchellJ, TalbotK. The SMA Trust: the role of a disease-focused research charity in developing treatments for SMA. Gene Ther. 24(9), 544–546 (2017).

Discover further insights in our exclusive interview on Neuro Central

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.